Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis

Clinical Therapeutics

Volumn 26, Issue 4, 2004, Pages 493-501

  Kuti, Joseph L ^a   Nightingale, Charles H ^a   Knauft, R Frederic ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Continuous infusion; Cystic fibrosis; Meropenem; Pharmacodynamics; Pharmacokinetics

Indexed keywords

MEROPENEM;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD CHEMISTRY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYSTIC FIBROSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; DRUG STABILITY; DRUG TOLERABILITY; ENZYME ANALYSIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFUSION; INFUSION PUMP; LABORATORY TEST; MALE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SAMPLING;

EID: 2342635820     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(04)90051-3     Document Type: Article

References (30)

1. Doring G, Conway SP, Heijerman HG, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: A European consensus. Eur Respir J. 2000;16:749-767.
2. Høiby N. New antimicrobials in the management of cystic fibrosis. J Antimicrob Chemother. 2002;49:235-238.
3. Byrne S, Maddison J, Connor P, et al. Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients. J Antimicrob Chemother. 1995;35(Suppl A):135-143.
4. Ciofu O, Jensen T, Pressler T, et al. Meropenem in cystic fibrosis patients infected with resistant Pseudomonas aeruginosa or Burkholderia cepacia and with hypersensitivity to beta-lactam antibiotics. Clin Microbiol Infect. 1996;2:91-98.
5. Turnidge JD. The pharmacodynamics of β-lactams. Clin Infect Dis. 1998;27:10-22.
6. Walker R, Andes D, Conklin J, et al. Pharmacodynamic activity of meropenem in an animal infection model. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando). Washington, DC: American Society for Microbiology; 1994:147. Abstract.
7. Drusano GL. Prevention of resistance: A goal for dose selection for antimicrobial agents. Clin Infect Dis. 2003;36(Suppl 1):S42-S50.
8. Grant EM, Kuti JL, Nicolau DP, et al. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy. 2002;22:471-483.
9. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother. 1998;42:521-527.
10. Patel RP, Cook SE. Stability of meropenem in intravenous solutions. Am J Health Syst Pharm. 1997;54:412-421.
11. Viaene E, Chanteux H, Servais H, et al. Comparative stability studies of antipseudomonal β-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother. 2002;46:2327-2332.
12. Walker SE, Varrin S, Yannicelli D, Law S. Stability of meropenem in saline and dextrose solutions and compatibility with potassium chloride. Can J Hosp Pharm. 1998;51:156-168.
13. Grant EM, Zhong MK, Ambrose PG, et al. Stability of meropenem in a portable infusion device in a cold pouch. Am J Health Syst Pharm. 2000;57:992-995.
14. Merrem [package insert]. Wilmington, Del: AstraZeneca Pharmaceuticals LP; 2001.
15. Elkhaili H, Niedergang S, Pompei D, et al. High-performance liquid chromatography assay for meropenem in serum. J Chromatogr B Biomed Appl. 1996;686:19-26.
16. Florea NR, Kotapati S, Kuti JL, et al. Cost analysis of continuous versus intermittent infusion piperacillin-tazobactam: A time-motion study. Am J Health Syst Pharm. 2003;60:2321-2327.
17. David TJ, Devlin J. Continuous infusion of ceftazidime in cystic fibrosis. Lancet. 1989;1:1454-1455.
18. Kuzemko J, Crawford C. Continuous infusion of ceftazidime in cystic fibrosis. Lancet. 1989;2:385.
19. Vinks AA, Brimicombe RW, Heijerman HG, Bakker W. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: Clinical outcome, microbiology, and pharmacokinetics. J Antimicrob Chemother. 1997;40:125-133.
20. Rappaz I, Decosterd LA, Bille J, et al. Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children. Eur J Pediatr. 2000;159:919-925.
21. Byl B, Baran D, Jacobs F, et al. Serum pharmacokinetics and sputum penetration of amikacin 30 mg/kg once daily and of ceftazidime 200 mg/kg/day as a continuous infusion in cystic fibrosis patients. J Antimicrob Chemother. 2001;48:325-327.
22. Christenson JC, Korgenski EK, Daly JA. In vitro activity of meropenem, imipenem, cefepime and ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Antimicrob Chemother. 2000;45:899-901.
23. NCCLS. Performance Standards for Antimicrobial Susceptibility Testing: Eleventh Informational Supplement M100-S11. Wayne, Pa: NCCLS; 2002.
24. Christensson BA, Ljungberg B, Eriksson L, Nilsson-Ehle I. Pharmacokinetics of meropenem in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis. 1998;17:873-876.
25. Bui KQ, Ambrose PG, Nicolau DP, et al. Pharmacokinetics of high-dose meropenem in adult cystic fibrosis patients. Chemotherapy. 2001;47:153-156.
26. Reed MD, Stern RC, O'Brien CA, et al. Pharmacokinetics of imipenem and cilastatin in patients with cystic fibrosis. Antimicrob Agents Chemother. 1985;27:583-588.
27. Sorgel F, Stephan U, Wiesemann HG, et al. High dose treatment with antibiotics in cystic fibrosis - a reappraisal with special reference to the pharmacokinetics of beta-lactams and new fluoroquinolones in adult CF-patients. Infection. 1987;15:385-396.
28. de Groot R, Hack BD, Weber A, et al. Pharmacokinetics of ticarcillin in patients with cystic fibrosis: A controlled prospective study. Clin Pharmacol Ther. 1990;47:73-78.
29. Wang JP, Unadkat JD, al-Habet SM, et al. Disposition of drugs in cystic fibrosis. IV. Mechanisms for enhanced renal clearance of ticarcillin. Clin Pharmacol Ther. 1993;54:293-302.
30. Vinks AA, den Hollander JG, Overbeek SE, et al. Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis. Antimicrob Agents Chemother. 2003;47:541-547.